JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 126 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2 | -99.8% | 2 | -99.2% | 0.00% | – |
| Q3 2022 | $1,000 | – | 237 | +507.7% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 39 | -100.0% | 0.00% | -100.0% |
| Q3 2021 | $1,232,000 | -67.1% | 165,863 | -69.9% | 0.00% | -50.0% |
| Q2 2021 | $3,744,000 | -27.7% | 550,562 | +9.1% | 0.00% | -33.3% |
| Q1 2021 | $5,182,000 | +5594.5% | 504,583 | +4152.0% | 0.00% | – |
| Q2 2018 | $91,000 | -71.7% | 11,867 | -17.1% | 0.00% | – |
| Q1 2018 | $321,000 | +93.4% | 14,317 | +34.4% | 0.00% | – |
| Q3 2017 | $166,000 | – | 10,656 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 4,447,829 | $30,245,000 | 89.29% |
| TRV GP III, LLC | 3,048,780 | $20,732,000 | 3.62% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 250,644 | $1,704,000 | 0.76% |
| PFM Health Sciences, LP | 3,262,833 | $22,187,000 | 0.70% |
| Yorktown Management & Research Co Inc | 56,600 | $385,000 | 0.30% |
| Sofinnova Investments, Inc. | 624,756 | $4,248,000 | 0.24% |
| Omega Fund Management, LLC | 275,513 | $1,873,000 | 0.21% |
| PATHWAY CAPITAL MANAGEMENT, LP | 60,279 | $410,000 | 0.16% |
| Orbimed Advisors | 2,147,400 | $14,602,000 | 0.15% |
| Grace Capital | 18,669 | $127,000 | 0.08% |